Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03287804 · OUTCOME

Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period

APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma · Source last updated 2020-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 28 days post-infusion

Analysis population: Patients who received at least 1 dose (complete or partial) of AUTO2 therapy (infused set)

Groups in this outcome

AUTO2

Relapsed or refractory myeloma patients

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AUTO211

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AUTO20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
groups
  1. description
    Relapsed or refractory myeloma patients
    id
    OG000
    title
    AUTO2
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients who received at least 1 dose (complete or partial) of AUTO2 therapy (infused set)
reporting Status
POSTED
time Frame
Up to 28 days post-infusion
title
Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice